Design and Rationale for a Phase III, Double-blind, Placebo-controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small-cell Lung Cancer: The AEGEAN Trial
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2007 ◽
Vol 25
(25)
◽
pp. 3945-3951
◽
Keyword(s):
2007 ◽
Vol 2
(8)
◽
pp. S359
◽
Keyword(s):
Keyword(s):
2008 ◽
Vol 26
(15_suppl)
◽
pp. 8045-8045
◽
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. 7527-7527
Keyword(s):
Keyword(s):
Keyword(s):